Literature DB >> 33208295

Risk Factors for Surgical Shunting in a Large Cohort With Ischemic Priapism.

Hanson Zhao1, Kai Dallas1, John Masterson1, Eric Lo2, Justin Houman1, Carl Berdahl3, Joshua Pevnick4, Jennifer T Anger5.   

Abstract

BACKGROUND: Ischemic priapism is treated with a stepwise algorithm, but some patients may benefit from immediate shunt placement. AIM: To identify risk factors for surgical shunt placement in a large series of patients with ischemic priapism.
METHODS: We identified all patients presenting to our institution with ischemic priapism from January 2010 to December 2018. Multivariable was performed to assess risk factors for surgical shunting. Receiver operating characteristic curve analysis (Youden Index) was used to assess which cutoff time for the duration of priapism was most predictive requiring shunting. OUTCOMES: We assess risk factors for surgical shunting and what duration of priapism was most predictive of requiring a shunt.
RESULTS: We identified a total of 169 ischemic priapism encounters from 143 unique patients, of which 26 (15%) encounters resulted in a surgical shunt. Patients treated with a shunt had longer priapism durations than those without (median 36 vs 10 hours, P < .001). Independent predictors of a surgical shunt on multivariate logistic regression were the duration of priapism in hours (odds ratio: 1.05, 95% confidence interval: 1.02-1.10; P < .001) and history of prior priapism (odds ratio: 3.15, 95% confidence interval: 1.03-9.60; P = .045). Receiver operating characteristic curve analysis using priapism duration to predict the need for shunt generated an area under curve of 0.83. A duration of 24 hours correlated to a sensitivity of 0.77 and specificity of 0.90. CLINICAL IMPLICATIONS: These results can be used to counsel future patients and assist in the decision-making process for providers. STRENGTHS & LIMITATIONS: This is one of the largest series of priapism in the literature. Most (74%) of the priapism were due to intracavernosal injections so the results may not be generalizable to populations with different priapism etiologies.
CONCLUSION: In this study of 169 priapism encounters, we found that the priapism duration and history of prior priapism were independent predictors of surgical shunt placement. These results can aid urologists in the counseling and decision-making process of these challenging cases. Zhao H, Dallas K, Masterson J, et al. Risk Factors for Surgical Shunting in a Large Cohort With Ischemic Priapism. J Sex Med 2020;17:2472-2477.
Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intracavernosal Injections; Ischemic Priapism; Priapism; Surgical Shunt

Mesh:

Year:  2020        PMID: 33208295      PMCID: PMC8136145          DOI: 10.1016/j.jsxm.2020.09.007

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  18 in total

1.  American Urological Association guideline on the management of priapism.

Authors:  Drogo K Montague; Jonathan Jarow; Gregory A Broderick; Roger R Dmochowski; Jeremy P W Heaton; Tom F Lue; Ajay Nehra; Ira D Sharlip
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

Review 2.  Guideline of guidelines: priapism.

Authors:  Asif Muneer; David Ralph
Journal:  BJU Int       Date:  2016-12-29       Impact factor: 5.588

Review 3.  European Association of Urology guidelines on priapism.

Authors:  Andrea Salonia; Ian Eardley; François Giuliano; Dimitrios Hatzichristou; Ignacio Moncada; Yoram Vardi; Eric Wespes; Konstantinos Hatzimouratidis
Journal:  Eur Urol       Date:  2013-11-16       Impact factor: 20.096

Review 4.  Standard operating procedures for priapism.

Authors:  Arthur L Burnett; Ira D Sharlip
Journal:  J Sex Med       Date:  2012-03-29       Impact factor: 3.802

5.  Low-flow priapism: risk factors for erectile dysfunction.

Authors:  M S El-Bahnasawy; A Dawood; A Farouk
Journal:  BJU Int       Date:  2002-02       Impact factor: 5.588

6.  Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model.

Authors:  A Muneer; S Cellek; A Dogan; P D Kell; D J Ralph; S Minhas
Journal:  Int J Impot Res       Date:  2005 Jan-Feb       Impact factor: 2.896

7.  Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?

Authors:  Michael E Rezaee; Martin S Gross
Journal:  J Sex Med       Date:  2020-07-02       Impact factor: 3.802

Review 8.  Advances in the understanding of priapism.

Authors:  Matthew Hudnall; Amanda B Reed-Maldonado; Tom F Lue
Journal:  Transl Androl Urol       Date:  2017-04

Review 9.  Recent advances in the management of priapism.

Authors:  Asif Muneer; Hussain M Alnajjar; David Ralph
Journal:  F1000Res       Date:  2018-01-10

Review 10.  Avoiding complications: surgery for ischemic priapism.

Authors:  Amanda B Reed-Maldonado; Janet S Kim; Tom F Lue
Journal:  Transl Androl Urol       Date:  2017-08
View more
  1 in total

Review 1.  Conservative and medical treatments of non-sickle cell disease-related ischemic priapism: a systematic review by the EAU Sexual and Reproductive Health Panel.

Authors:  Andrea Salonia; Suks Minhas; Paolo Capogrosso; Kostas Dimitropolous; Giorgio Ivan Russo; Tharu Tharakan; Uros Milenkovic; Andrea Cocci; Luca Boeri; Murat Gül; Carlo Bettocchi; Joana Carvalho; Arif Kalkanlı; Giovanni Corona; Georgios Hatzichristodoulou; Hugh T Jones; Ates Kadioglu; Juan Ignacio Martinez-Salamanca; Vaibhav Modgil; Ege Can Serefoglu; Paolo Verze
Journal:  Int J Impot Res       Date:  2022-08-22       Impact factor: 2.408

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.